On the morning of May 11, the 6th Asia Summit on Global Health (ASGH), co-hosted by the HKSAR Government and the Hong Kong Trade Development Council, opened at the Hong Kong Convention and Exhibition Centre. Cheng Cheung Ling, President of Chia Tai Pharmaceutical Group and Vice Chair of the Board of Directors of Sino Biopharm (1177.HK), and Theresa Tse, Chair of the Board of Directors of Sino Biopharm, were invited to attend. On the same day, Sino Biopharm announced an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the marketing process of the first-in-class (FIC) new drug Bepirovirsen in China. This news attracted widespread attention at the summit. 

In his opening speech, John Lee Ka-chiu, Chief Executive of the Hong Kong Special Administrative Region, stated that the summit provides a convenient platform for medical development and research collaboration, bringing extensive opportunities for exchange, networking, and innovative cooperation. The discussions focused on topics such as aligning with the opportunities of the national "15th Five-Year Plan", global trends in medical development, and health innovation and investment trends. He also emphasized that the HKSAR Government attaches great importance to and fully promotes the development of medical innovation. It has established key infrastructure, introduced effective policies, and created a vibrant industrial ecosystem network capable of efficiently translating research achievements into practical solutions. He mentioned that the "GBA International Clinical Trial Institute" located in the Hong Kong Park of the Hetao Loop has commenced operations, working in synergy with the "GBA International Clinical Trial Center" in Shenzhen to accelerate the delivery of cutting-edge medical technologies to patients. 

In the themed sharing session "Driving New Breakthroughs in Healthcare", the exclusive strategic partnership between Sino Biopharm and GlaxoSmithKline (GSK) received significant attention. Theresa Tse stated that Sino Biopharm will spare no effort to bring more innovative medicines and treatment plans to patients in need, as "warming more lives with health technology" is the very meaning of the pharmaceutical industry. She pointed out that pharmaceutical innovation is like a long marathon because it is high-risk and capital-intensive. Future pharmaceutical innovation will not be a solo effort but will require a closely connected ecosystem that gathers global resources from technology, talent, clinical fields, and more. 

Sino Biopharm hopes to soon become a large multinational pharmaceutical company that connects global resources, and is also committed to becoming the preferred partner in China for leading global multinational pharmaceutical companies, "because the whole world needs the wave of rapid innovation that is happening in China".She further pointed out that with the addition of artificial intelligence, future innovation will be faster and more exciting. China's healthcare sector is in a transformative era, and Hong Kong is in a very favorable position to play a greater, even leading, role. 

Jonathan Symonds, Chairman of the Board of GSK, stated in his sharing that this collaboration is a complementary partnership between two industry giants that will ultimately bring disruptive changes and tangible clinical benefits to patients with hepatitis B. China has a huge hepatitis B market, with an affected population of about 75 million. Five to ten years ago, GSK would have undoubtedly chosen to advance this project independently, building its own sales team for commercialization. Today, however, China's pharmaceutical industry has matured, and leading local companies represented by Sino Biopharm have developed solid professional capabilities and mature commercialization advantages. We are more confident that through deep collaboration with Sino Biopharm, a leader in China's liver disease field, this innovative therapy can benefit the Chinese patient population faster and more broadly. 

With the theme "Driving New Breakthroughs in Healthcare", this year's forum brought together over 90 experts and industry representatives from 15 countries and regions to discuss the prospects and business opportunities of the healthcare industry, focusing on hot topics such as artificial intelligence, the "15th Five-Year Plan", and the silver economy. 

Declaration:

The copyright of this article is owned by the original author or the Company. It may not be used by reprinting, copying, filming, adapting, compiling, or other means without authorization. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited. 
Source: Xinhua News, Wen Wei Po (Hong Kong)